Tau protein — Drug Target

All drugs that target Tau protein — marketed and clinical-stage. Includes 4 drug classes acting on this target.

Drug classes

Tau protein aggregation inhibitor · tau aggregation inhibitor · tau protein inhibitor · Tau aggregation inhibitor

Marketed (1)

• TAU · Montefiore Medical Center · Tau protein aggregation inhibitor · Neurology
  Tau protein aggregation inhibitor.

Phase 3 pipeline (4)

• TRx0237 · TauRx Therapeutics Ltd · tau aggregation inhibitor · Neurology
  TRx0237 is a tau aggregation inhibitor.
• RVT-101 · Axovant Sciences Ltd. · tau protein inhibitor · Neurology
  RVT-101 is a small molecule that targets the tau protein to treat neurodegenerative diseases.
• TAU-284 · Tanabe Pharma Corporation · Tau aggregation inhibitor · Neurology
  Tau-284 is a tau aggregation inhibitor.
• Experimental: ALZ-801 · Alzheon Inc. · Tau aggregation inhibitor · Neurology
  ALZ-801 is a small-molecule inhibitor of tau protein aggregation that crosses the blood-brain barrier to reduce pathological tau accumulation in the brain.

Phase 2 pipeline (1)

• ACI-7104.056 at Dose A · AC Immune SA · Tau aggregation inhibitor · Neurology
  ACI-7104.056 is a tau aggregation inhibitor.